obecabtagene autoleucel
autolus
['felix']
solid data from $autl ph2 felix study of obe-cel in all at #asco2023: met primary endpoint with 76% of 112 all patients responding (cr/cri) shares down over 6% with sell the news reaction this morning, $autl was up 72% in may 
Biotech stock analyst. Editor of Biotech Millionaire at Mauldin Economics. Tweets and opinions are not investment advice.